ArticleFrontiers in pharmacology2025
Adherence, satisfaction, and quality of life in Wilson disease patients after switching to trientine tetrahydrochloride: observational data from a dual cohort study.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Wilson disease (WD) is a rare genetic disorder requiring lifelong treatment. Adherence to therapy is thus of utmost importance. We aimed to assess the change in treatment adherence and satisfaction in adult patients with WD after transitioning to trientine tetrahydrochloride (TETA 4HCl), a first-of-its-kind investigation. Methods: Observational, Italian multicenter study of adult patients switched to TETA 4HCl by their treating physicians. Eligibility criteria included WD patients either already switched (up to a maximum of 9 months before enrolment; retrospective-prospective [RP] cohort) or about to be switched (within 3 months following enrolment; prospective [P] cohort). Adherence was assessed by pill counts, self-reported Morisky Medication Assessment Scale and 24-h urinary copper excretion (UCE) values within expected range. Patient reported Experiences and Satisfaction with Medications and health related quality of life questionnaires were completed at baseline (T0) and after 3 months (T1). Results: 25 patients were enrolled: 9 in the RP and 16 in the P cohort, with median (IQR) age and time since diagnosis was 43.0 [(30.0, 52.0)] years and 24.0 [(14.0, 30.0)] years respectively. At T0, 40% of patients self- reported adherence according to MMAS and 58.3% were considered adherent according to UCE values. At T1, values increased to 64% (for both MMAS and UCE). Pill count (T1) suggested that 64% could be considered adherent. On a ten-point Likert scale from -5 to +5, median (IQR) satisfaction score was 4.0 [(4.0, 5.0)]. All quality-of-life (QoL) domains improved between T0 and T1. Conclusion: Adults with WD on maintenance therapy following a switch in therapy to TETA 4HCl some improvements in adherence, satisfaction and QoL were observed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.